Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Trastornos del Movimiento
FILTRAR POR:
Por tema
3323 ARTÍCULOS , VIENDO DEL 2161 AL 2175
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial
Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group.
Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10.
Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial
Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH; Pramipexole ER Studies Group.
Neurology. 2011 Aug 23;77(8):759-66. doi: 10.1212/WNL.0b013e31822affb0. Epub 2011 Aug 10.
MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study
Morelli M, Arabia G, Novellino F, Salsone M, Giofrè L, Condino F, Messina D, Quattrone A.
Neurology. 2011 Sep 13;77(11):1042-7. doi: 10.1212/WNL.0b013e31822e55d0. Epub 2011 Aug 10.
Organotypic vibrosections: novel whole sagittal brain cultures
Ullrich C, Daschil N, Humpel C.
J Neurosci Methods. 2011 Sep 30;201(1):131-41. doi: 10.1016/j.jneumeth.2011.07.021. Epub 2011 Jul 30.
Functional connectivity and integrative properties of globus pallidus neurons
Jaeger D, Kita H.
Neuroscience. 2011 Dec 15;198:44-53. doi: 10.1016/j.neuroscience.2011.07.050. Epub 2011 Jul 27.
Site of deep brain stimulation and jaw velocity in Parkinson disease
Robertson LT, St George RJ, Carlson-Kuhta P, Hogarth P, Burchiel KJ, Horak FB.
J Neurosurg. 2011 Nov;115(5):985-94. doi: 10.3171/2011.7.JNS102173. Epub 2011 Aug 12.
An update on adenosine A2A receptors as drug target in Parkinson's disease
Vallano A, Fernandez-Duenas V, Pedros C, Arnau JM, Ciruela F.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):659-69. doi: 10.2174/187152711797247803.
Drug targets from genetics: α-synuclein
Danzer KM, McLean PJ.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):712-23. doi: 10.2174/187152711797247867.
Editorial hot topic: drug targets in Parkinson's disease: where are we and where should we go?]
Cookson MR.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):650. doi: 10.2174/187152711797247830.
Is rTMS an effective therapeutic strategy that can be used to treat Parkinson's disease?
Arias-Carrion O, Machado S, Paes F, Velasques B, Teixeira S, Cardenas-Morales L, Piedade R, Ribeiro P, Nardi AE.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):693-702. doi: 10.2174/187152711797247821.
GDNF family ligands: a potential future for Parkinson's disease therapy
Mickiewicz AL, Kordower JH.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):703-11. doi: 10.2174/187152711797247876.
Cenci MA, Ohlin KE, Odin P.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):670-84. doi: 10.2174/187152711797247885.
Targeting nicotinic receptors for Parkinson's disease therapy
Quik M, Bordia T, Huang L, Perez X.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):651-8. doi: 10.2174/187152711797247849.
Kinases as targets for Parkinson's disease: from genetics to therapy
Vancraenenbroeck R, Lobbestael E, Maeyer MD, Baekelandt V, Taymans JM.
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):724-40. doi: 10.2174/187152711797247858.
Hashizume A, Watanabe H, Matsuo K, Katsuno M, Tanaka F, Nagatani T, Sobue G.
J Neurol Sci. 2011 Oct 15;309(1-2):148-50. doi: 10.1016/j.jns.2011.07.025. Epub 2011 Aug 12.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.